Parthenolide repressed endometriosis induced surgically in rats: Role of PTEN/PI3Kinase/AKT/GSK-3β/β-catenin signaling in inhibition of epithelial mesenchymal transition
Lab / animal
OA: closed
CC0
⤵ 1 in-corpus citation
AI-generated summary
Parthenolide repressed surgically induced endometriosis in rats by inhibiting epithelial-mesenchymal transition through the PTEN/PI3K/AKT/GSK-3β/β-catenin signaling pathway.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
AIM: PI3K/AKT/GSK-3β/β-catenin signaling pathway is a triggering factor for epithelial to mesenchymal transition (EMT) which plays a pivotal role in the pathogenesis of endometriosis. Parthenolide is a sesquiterpene lactone extract that has anti-inflammatory, analgesic and anticancer properties. Hence, we investigated the effect of parthenolide against EMT in the endometrial tissue implants and immortalized epithelial endometriotic cell lines 12Z.
MAIN METHODS: Twenty- four female Rats with surgically induced endometriosis were treated with parthenolide (2, 4 mg/kg), for 4 weeks. Endometriotic cell line 12Z was used to identify the effect of parthenolide on the wound healing, cellular migration and invasion properties of endometriotic cells.
KEY FINDINGS: Parthenolide decreased the endometriotic implant tissue expression of total PI3K, PI3K-p85, p-AKT, p/total AKT, p-GSK-3β, P/total GSK-3β, and nβ-catenin, as well as increased E-cadherin and decreased vimentin mRNA expression. Parthenolide upregulated PTEN immunoreactivity as well as the endometriotic tissue caspase-3, caspase-9, BAX levels while reducing Bcl2 level. Additionally, parthenolide decreased endometriotic tissue implants surface area and histopathological score of the epithelial growth.
SIGNIFICANCE: Our findings showed that parthenolide in a dose dependent manner inhibited PI3K/AKT/GSK-3β/nβ-catenin cascade via enhancement of PTEN with subsequent inhibition of EMT evidenced by elevation of the epithelial marker, E-cadherin and reduction of mesenchymal marker, vimentin, of the endometriotic implants in addition to reversal of invasion and migration properties of epithelial endometriotic cell lines. These findings provide a valuable therapeutic approach for treatment of endometriosis.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (61)
- 17betaE2 promotes cell proliferation in endometriosis by decreasing PTEN via NFkappaB-dependent pathway via openalex
- Ameliorative Effects of Quercetin and Metformin and Their Combination Against Experimental Endometriosis in Rats via openalex
- Angiogenesis and endometriosis via openalex
- Apoptosis in human endometrium and endometriosis via openalex
- Atorvastatin causes regression of endometriotic implants in a rat model via openalex
- Daidzein-rich isoflavone aglycones inhibit cell growth and inflammation in endometriosis via openalex
- Endometriotic cells are resistant to interferon-gamma-induced cell growth inhibition and apoptosis: a possible mechanism involved in the pathogenesis of endometriosis via openalex
- Epithelial-to-mesenchymal transition in the development of endometriosis via openalex
- Expression of selected tumor suppressor and oncogenes in endometrium of women with endometriosis via openalex
- Interleukin-22 secreted by ectopic endometrial stromal cells and natural killer cells promotes the recruitment of macrophages through promoting CCL2 secretion via openalex
- In Vitro and In Vivo Effects of Tumor Suppressor Gene PTEN on Endometriosis: An Experimental Study via openalex
- In vitro effects of a small-molecule antagonist of the Tcf/ß-catenin complex on endometrial and endometriotic cells of patients with endometriosis via openalex
- In-vitro models of human endometriosis via openalex
- PI3K/AKT pathway is altered in the endometriosis patient's endometrium and presents differences according to severity stage via openalex
- Secreted frizzled-related protein 2 (SFRP2) expression promotes lesion proliferation via canonical WNT signaling and indicates lesion borders in extraovarian endometriosis via openalex
- Serial analysis of gene expression reveals differential expression between endometriosis and normal endometrium. Possible roles for AXL and SHC1 in the pathogenesis of endometriosis via openalex
- The Origin and Pathogenesis of Endometriosis via openalex
- Time to redefine endometriosis including its pro-fibrotic nature via openalex
- β-catenin signaling inhibitors ICG-001 and C-82 improve fibrosis in preclinical models of endometriosis via openalex
- W2606513998 via openalex
- W2612133931 via openalex
- W2618632515 via openalex
- W2751080201 via openalex
- W2766723766 via openalex
- W2781813834 via openalex
- W2798260604 via openalex
- W2803306454 via openalex
- W2808015032 via openalex
- W2909281294 via openalex
- W2938022022 via openalex
- W2962586713 via openalex
- W2969770152 via openalex
- W3124678786 via openalex
- W3167776014 via openalex
- W3177845102 via openalex
- W4281944024 via openalex
- W6642880528 via openalex
- W6675698577 via openalex
- W6680959544 via openalex
- W6747906291 via openalex
- W6769958332 via openalex
- W1968013406 via openalex
- W6771374719 via openalex
- W1971586374 via openalex
- W1994682335 via openalex
- W2021159269 via openalex
- W2037451324 via openalex
- W2064847453 via openalex
- W2070731236 via openalex
- W2072503088 via openalex
- W2078606646 via openalex
- W2084228958 via openalex
- W2092209895 via openalex
- W2099486836 via openalex
- W2106651240 via openalex
- W2126371827 via openalex
- W2140777557 via openalex
- W2148124890 via openalex
- W2172100996 via openalex
- W2339269407 via openalex
- W2584071154 via openalex
Cited by (1)
Source provenance
- europepmc
- last seen: 2026-10-15T06:08:49.021275+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-10-15T06:07:33.367182+00:00
License: CC0
· commercial use OK